

CITATION REPORT

List of articles citing

Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD

DOI: 10.1002/humu.21136

Human Mutation, 2010, 31, 41-51.

Source: <https://exaly.com/paper-pdf/48106463/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
311	A novel succinate dehydrogenase type B mutation in an Iranian family. Its genetic and clinical evaluation. 2014 , 13, 568-73		
310	L157X nonsense mutation of the succinate dehydrogenase subunit B gene in a Japanese patient with right paraaortic paraganglioma. 2010 , 38, 18-23		3
309	Genetic testing for pheochromocytoma. 2010 , 12, 456-64		46
308	Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. <i>Human Mutation</i> , 2010 , 31, 41-51	4.7	286
307	Are we overestimating the penetrance of mutations in SDHB?. <i>Human Mutation</i> , 2010 , 31, 761-2	4.7	55
306	What are the mechanisms of tumor formation in patients with paraganglioma and SDHB germline mutations?. 2010 , 55, 212-212		
305	PHD2 in tumour angiogenesis. 2010 , 103, 1-5		51
304	Mendelian genetics of rare--and not so rare--cancers. 2010 , 1214, 70-82		27
303	Pheochromocytomas detected by biochemical screening in predisposed subjects are associated with lower prevalence of clinical and biochemical manifestations and smaller tumors than pheochromocytomas detected by signs and symptoms. 2010 , 163, 121-7		16
302	Advances in the genetics of familial renal cancer. 2010 , 15, 532-8		19
301	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. 2011 , 18, 73-83		45
300	Identification of a 4.9-kilo base-pair Alu-mediated founder SDHD deletion in two extended paraganglioma families from Austria. 2010 , 55, 182-5		4
299	Succinate dehydrogenase - Assembly, regulation and role in human disease. 2010 , 10, 393-401		233
298	3. Pheochromocytoma. 2011 , 77-127		2
297	Genetics of familial renal cancers. 2011 , 118, e21-6		26
296	Hypothesis: environmental regulation of 5-hydroxymethylcytosine by oxidative stress. 2011 , 6, 853-6		122
295	Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. 2011 , 364, 885-6		95

294	Hereditary paragangliomas. 2011 , 70, 99-106	19
293	Modern PET imaging for paragangliomas: relation to genetic mutations. 2011 , 37, 662-8	17
292	Adenomatoid tumour of the adrenal gland in a patient with germline SDHD mutation: a case report and review of the literature. 2011 , 43, 495-8	8
291	Functional consequences of succinate dehydrogenase mutations. 2011 , 17 Suppl 3, 64-71	15
290	Renal tumors associated with germline SDHB mutation show distinctive morphology. 2011 , 35, 1578-85	155
289	Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. 2011 , 75, 650-5	38
288	SDH mutations in cancer. 2011 , 1807, 1432-43	257
287	Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. 2011 , 88, 402-21	44
286	Novel germline SDHD mutation: diagnosis and implications to the patient. 2011 , 10, 365-71	0
285	Meet me halfway: when genomics meets structural bioinformatics. 2011 , 4, 281-303	10
284	[Paragangliomas and paraganglioma syndromes]. 2011 , 90 Suppl 1, S56-82	9
283	Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. 2011 , 96, 375-84	65
282	Translational Endocrinology & Metabolism: Neoplasia Update. 2011 ,	
281	Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. 2011 , 152, 2133-40	35
280	A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. 2011 , 7, 749-55	9
279	Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. 2011 , 96, E1279-82	83
278	Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. 2011 , 18, R253-76	248
277	No child left behind in SDHB testing for paragangliomas and pheochromocytomas. 2011 , 29, 4070-2	13

276	Familial pediatric endocrine tumors. 2011 , 16, 1388-96	10
275	SDM--a server for predicting effects of mutations on protein stability and malfunction. 2011 , 39, W215-22	343
274	Novel SDHD gene mutation (H102R) in a patient with metastatic cervical paraganglioma effectively treated by peptide receptor radionuclide therapy. 2011 , 29, e812-5	10
273	Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. 2012 , 4, 808-20	4
272	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. 2012 , 19, 149-55	61
271	Genetic testing by cancer site: urinary tract. 2012 , 18, 343-9	6
270	The genetics of pheochromocytoma: using clinical features to guide genetic testing. 2012 , 166, 151-8	83
269	Genetic testing by cancer site: endocrine system. 2012 , 18, 364-71	12
268	Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. 2012 , 44, 390-9	83
267	Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. 2012 , 49, 768-76	98
266	2012 Meet-The-Professor: Endocrine Case Management. 2012 ,	
265	[Endocrine disease: progress in diagnosis and treatment topics: 1. Progress in diagnosis; 3. The handling of adrenal disease and problems, 2) Malignant pheochromocytoma and multiple endocrine neoplasia (MEN), emphasizing importance of genetic testing]. 2012 , 101, 949-58	
264	Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. 2012 , 44, 285-92	135
263	Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?. 2012 , 97, E357-66	116
262	Identical germline mutations in the TMEM127 gene in two unrelated Japanese patients with bilateral pheochromocytoma. 2012 , 77, 707-14	11
261	Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. 2012 , 188, 2063-71	175
260	Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. 2012 , 79, 1187.e1-7	51
259	Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. 2012 , 205, 1-11	142

258	SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. 2012 , 12, 408	46
257	Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. 2012 , 26, 4506-16	33
256	Late diagnosis of an index case of SDH-related paraganglioma/pheochromocytoma syndrome. 2012 , 59, 148-150	
255	Late diagnosis of an index case of SDH-related paraganglioma/pheochromocytoma syndrome. 2012 , 59, 148-50	1
254	Carney Stratakis syndrome in a patient with SDHD mutation. 2012 , 23, 181-6	5
253	Head and neck paragangliomas: clinical and molecular genetic classification. 2012 , 67 Suppl 1, 19-28	105
252	Genetic and clinical characteristics of head and neck paragangliomas in a Chinese population. 2012 , 122, 1761-6	10
251	State of the science: an update on renal cell carcinoma. 2012 , 10, 859-80	121
250	Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. 2012 , 23, 4-14	87
249	High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands. 2012 , 81, 284-8	43
248	Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome. 2012 , 11, 115-21	16
247	Sporadic or familial head neck paragangliomas enrolled in a single center: clinical presentation and genotype/phenotype correlations. 2013 , 35, 23-7	7
246	Cancer of the Kidney and Urogenital Tract. 2013 , 1-17	
245	Évaluation fonctionnelle par TEP 18F-FDopa des paragangliomes et phéochromocytomes non métastatiques : impact de la localisation lésionnelle et du statut génétique. 2013 , 37, 116-123	1
244	An update on the genetics of pheochromocytoma. 2013 , 27, 141-7	45
243	Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. 2013 , 78, 898-906	48
242	Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. 2013 , 24, 199-205	37
241	Renal cancer in von Hippel-Lindau disease and related syndromes. 2013 , 9, 529-38	46

240	Role of hypoxia and HIF2 α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. 2013 , 68, 285-317	30
239	Diagnosis of silent pheochromocytoma and paraganglioma. 2013 , 8, 47-57	6
238	Secondary Hypertension: Pheochromocytoma. 2013 , 89-98	
237	Paragangliomas: update on differential diagnostic considerations, composite tumors, and recent genetic developments. 2013 , 30, 207-23	35
236	Mechanisms of Bioenergy Production in Mitochondria. 2013 , 99-121	
235	Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. 2013 , 20, 1444-50	153
234	SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. 2013 , 50, 919-30	580
233	Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. 2013 , 98, E1103-8	87
232	Genetic testing in head and neck paraganglioma: who, what, and why?. 2013 , 74, 236-40	11
231	Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation. 2013 , 20, 65-78	17
230	From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes: A Personal History. 2013 , 2, 1-86	
229	Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. 2013 , 18, 391-407	34
228	Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. 2013 , 20, L1-6	33
227	Endocrine Causes of Hypertension. 2013 , 490-500	
226	Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. 2013 , 105, 1270-83	122
225	Pheochromocytoma/Paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma. 2013 , 15, 428-34	51
224	Disomy as the genetic underlying mechanisms of loss of heterozygosity in SDHD-paragangliomas. 2013 , 98, E1012-6	4
223	Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. 2013 , 37, 234-40	145

222	Hereditary Neuroendocrine Tumor Syndromes. 2013 ,	2
221	Germline FH mutations presenting with pheochromocytoma. 2014 , 99, E2046-50	127
220	Pheochromocytoma and multiple endocrine neoplasia syndromes. 2014 , 533-568.e1	3
219	Parangliomas/Pheochromocytomas: clinically oriented genetic testing. 2014 , 2014, 794187	39
218	Non-pheochromocytoma (PCC)/paranglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. 2014 , 170, 1-12	122
217	Genetics of hereditary head and neck parangliomas. 2014 , 36, 907-16	52
216	The genetics of endocrine neoplasia. 2014 , 38, 262-73	
215	Phaeochromocytoma and paranglioma: next-generation sequencing and evolving Mendelian syndromes. 2014 , 14, 440-4	7
214	Genetic testing in the clinical care of patients with pheochromocytoma and paranglioma. 2014 , 21, 166-76	18
213	Phenotypic variability and risk of malignancy in SDHC-linked parangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133*). 2014 , 99, E489-96	17
212	Renal cell carcinoma in tuberous sclerosis complex. 2014 , 38, 895-909	147
211	Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations. 2014 , 32, 623-30	13
210	Diagnosis and management of pheochromocytoma. 2014 , 51, 151-87	37
209	Current concepts of pheochromocytoma. 2014 , 12, 469-74	27
208	Familial pheochromocytomas and parangliomas. 2014 , 386, 92-100	42
207	Pheochromocytoma and paranglioma: diagnosis, genetics, management, and treatment. 2014 , 38, 7-41	132
206	Parangliomas Arising in the Head and Neck: A Morphologic Review and Genetic Update. 2014 , 7, 543-57	10
205	Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. 2014 , 32, e10-3	24

204	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. 2014 , 14, 523	36
203	Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. 2014 , 99, 1915-42	1415
202	Genetic kidney cancer syndromes. 2014 , 12, 1347-55	19
201	Head and Neck Paragangliomas: Experience in 126 Patients With 162 Tumours. 2015 , 66, 332-341	9
200	2015 Meet-The-Professor: Endocrine Case Management. 2015 ,	
199	Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features. 2015 , 39, e1-e18	39
198	Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy. 2015 , 22, 283-93	15
197	Syndromes that Link the Endocrine System and Genitourinary Tract. 2015 , 31 Suppl 1, 155-71	
196	Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. 2015 , 6, 126	14
195	Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. 2015 , 2015, 296167	22
194	Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis. 2015 , 2015, 138573	47
193	15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas. 2015 , 22, T105-22	52
192	A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. 2015 , 24, 1836-42	39
191	Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation. 2015 , 100, E308-18	36
190	Mitochondrial sirtuins and their relationships with metabolic disease and cancer. 2015 , 22, 1060-77	87
189	Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. 2015 , 15, 440-8	66
188	Diagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma. 2015 , 49, 143-51	50
187	Head and neck paragangliomas: Experience in 126 patients with 162 tumours. 2015 , 66, 332-41	9

186	Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. 2015 , 28, 80-94	145
185	15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations. 2015 , 22, T71-82	39
184	15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5. 2015 , 22, T91-103	134
183	Hereditary Syndromes Involving Pheochromocytoma and Paraganglioma. 2016 , 221-234	1
182	Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects. 2016 , 67, 3-7	19
181	Endocrine Hypertension. 2016 , 556-588	6
180	Management of multicentric paragangliomas: Review of 24 patients with 60 tumors. 2016 , 38, 267-76	13
179	Diagnosis and Management of Hereditary Renal Cell Cancer. 2016 , 205, 85-104	4
178	Diagnosis and Management of Hereditary Pheochromocytoma and Paraganglioma. 2016 , 205, 105-24	4
177	Leukoencephalopathy due to Complex II Deficiency and Bi-Allelic SDHB Mutations: Further Cases and Implications for Genetic Counselling. 2017 , 33, 69-77	11
176	Low penetrance of paraganglioma and pheochromocytoma in an extended kindred with a germline SDHB exon 3 deletion. 2016 , 89, 128-32	14
175	Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances. 2016 ,	5
174	Rapid-sequence MRI for long-term surveillance for paraganglioma and pheochromocytoma in patients with succinate dehydrogenase mutations. 2016 , 175, 561-570	25
173	Syndromic gastrointestinal stromal tumors. 2016 , 14, 15	53
172	Screening for Genetic Susceptibility to Paediatric Tumours. 2016 , 35-50	
171	38 Biology and Genetics of Skull Base Tumors. 2016 ,	
170	Bronchial Paraganglioma with SDHB Deficiency. 2016 , 27, 332-337	2
169	A mutation of the succinate dehydrogenase B gene in a Korean family with paraganglioma. 2016 , 15, 601-6	3

168	The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. 2016 , 25, 231-8	68
167	Co-regulation of mitochondrial respiration by proline dehydrogenase/oxidase and succinate. 2016 , 48, 859-872	37
166	SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. 2016 , 108,	73
165	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. 2017 , 402, 787-798	2
164	Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging. 2017 , 141, 499-516	1
163	Genetic and epigenetic patterns in patients with the head-and-neck paragangliomas associate with differential clinical characteristics. 2017 , 143, 953-960	5
162	The phenotype of germline mutation carriers: a nationwide study. 2017 , 177, 115-125	27
161	JIMD Reports, Volume 33. 2017 ,	
160	Four generations of SDHB-related disease: complexities in management. 2017 , 16, 279-282	3
159	Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. 2017 , 23, e68-e75	127
158	SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. 2017 , 143, 1421-1435	43
157	Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of Disease. 2017 , 3, 1212-1213	2
156	Hereditary Kidney Cancer Syndromes and Surgical Management of the Small Renal Mass. 2017 , 44, 155-167	5
155	SDHA related tumorigenesis: a new case series and literature review for variant interpretation and pathogenicity. 2017 , 5, 237-250	35
154	Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. 2017 , 17, 445-457	17
153	Molecular Genetics of Pheochromocytoma and Paraganglioma. 2017 , 15-45	
152	GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES. 2017 , 23, 342-352	10
151	Cardiac paraganglioma with a novel germline mutation of succinate dehydrogenase gene D. 2017 , 47, 1193-1197	2

150	Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. 2017 , 23, 6733-6743	8
149	Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing. 2017 , 5, 602-607	5
148	Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis. 2017 , 87, 440-450	51
147	Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. 2017 , 102, 4013-4022	26
146	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. 2017 , 38, 489-515	151
145	Retroperitoneal paraganglioma-Is pre operative embolization useful?. 2017 , 39, 64-68	3
144	Counseling and Testing for Inherited Predisposition to Cancer. 2017 , 45-57	
143	Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). 2017 , 28, 253-268	11
142	Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management. 2017 , 38, 59-71	8
141	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. 2017 , 13, 233-247	140
140	Simple and rapid characterization of novel large germline deletions in SDHB, SDHC and SDHD-related paraganglioma. 2017 , 91, 536-544	3
139	Management of Adrenal Masses in Children and Adults. 2017 ,	4
138	Management of Locally Advanced and Metastatic Pheochromocytoma and Paraganglioma. 2017 , 277-300	1
137	Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. 2017 , 86, 286-296	28
136	Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers. 2017 , 16, 123-130	24
135	Radiological Surveillance Screening in Asymptomatic Succinate Dehydrogenase Mutation Carriers. 2017 , 1, 897-907	20
134	Head and neck paragangliomas: A two-decade institutional experience and algorithm for management. 2017 , 2, 380-389	34
133	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect.. 2017 , 1, 1-14	4

132	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. 2017 , 7,	14
131	Update on Modern Management of Pheochromocytoma and Paraganglioma. 2017 , 32, 152-161	72
130	The clinical genetics of phaeochromocytoma and paraganglioma. 2017 , 61, 490-500	15
129	Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation. 2018 , 109, 581-586	11
128	Morphological clues to the appropriate recognition of hereditary renal neoplasms. 2018 , 35, 184-192	2
127	Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype. 2018 , 372, 347-365	11
126	Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes , and. 2018 , 55, 384-394	97
125	Extent of surgery for phaeochromocytomas in the genomic era. 2018 , 105, e84-e98	20
124	Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. 2018 , 103, 438-445	38
123	A novel succinate dehydrogenase subunit B germline variant associated with head and neck paraganglioma in a Dutch kindred: A family-based study. 2018 , 43, 841-845	3
122	Exome analysis of carotid body tumor. 2018 , 11, 17	18
121	Nationwide study of patients with head and neck paragangliomas carrying SDHB germline mutations. 2018 , 2, 62-69	4
120	Pheochromocytomas and pituitary adenomas in three patients with exon deletions. 2018 , 25, L37-L42	43
119	Multifocal Paraganglioma and Pheochromocytoma Due to Truncated SDHD Mutation. 2018 , 116, 63-67	1
118	The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers. 2018 , 93, 60-66	33
117	Pheochromocytomas and Paragangliomas: Genetics and Pathophysiology. 2018 , 173-196	
116	Gene of the month: SDH. 2018 , 71, 95-97	19
115	DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas. 2018 , 178, R11-R17	18

114	Succinate dehydrogenase (SDH)-deficient neoplasia. 2018 , 72, 106-116	109
113	Pathology and genetics of pheochromocytoma and paraganglioma. 2018 , 72, 97-105	79
112	Predisposing Germline Mutations in Young Patients With Squamous Cell Cancer of the Oral Cavity.. 2018 , 2, 1-8	3
111	Succinate Dehydrogenase-Deficient Renal Cell Carcinoma: A Short Review. 2018 , 142, 1284-1288	15
110	Bayesian approach to determining penetrance of pathogenic SDH variants. 2018 , 55, 729-734	29
109	Secondary Hypertension. 2018 , 136-143	1
108	[Hereditary pheochromocytoma and paraganglioma: screening and follow-up strategies in asymptomatic mutation carriers]. 2018 , 79 Suppl 1, S10-S21	2
107	Familial Head and Neck Paraganglioma and Genetic Testing. 2018 , 231-241	
106	Cancer Syndromes That Present in Childhood. 2018 , 77-92	1
105	Pheochromocytomas, Paragangliomas and Disorders of the Sympathoadrenal System. 2018 ,	2
104	Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context. 2018 , 1870, 76-87	15
103	Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma. 2018 , 29, 169-175	20
102	Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers. 2018 , 26, 1339-1347	6
101	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. 2018 , 25, T201-T219	36
100	Imaging of cancer predisposition syndromes. 2018 , 48, 1364-1375	11
99	Pathology of Pheochromocytoma and Paraganglioma. 2018 , 15-37	2
98	Heritable and Syndromic Pheochromocytoma and Paraganglioma. 2018 , 63-87	
97	Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?. 2019 , 21, 104	6

96	Precision Surgery for Pheochromocytomas and Paragangliomas. 2019 , 51, 470-482	4
95	A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas. 2019 , 66, 671-680	12
94	Inherited Endocrine Neoplasia[A Comprehensive Review from Gland to Gene. 2019 , 7, 102-115	0
93	A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation. 2019 , 8,	10
92	Biochemically Silent Sympathetic Paraganglioma, Pheochromocytoma, or Metastatic Disease in SDHD Mutation Carriers. 2019 , 104, 5421-5426	4
91	Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms. 2019 , 8,	11
90	Imaging Features of Succinate Dehydrogenase-deficient Pheochromocytoma-Paraganglioma Syndromes. 2019 , 39, 1393-1410	21
89	The Impact Of Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review. 2019 , 12, 7929-7940	12
88	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of. 2019 , 7, 6	33
87	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. 2019 , 120, 1113-1119	42
86	Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration. 2019 , 11,	12
85	The loss of succinate dehydrogenase B expression is frequently identified in hemangioblastoma of the central nervous system. 2019 , 9, 5873	7
84	Higher risk of phaeochromocytoma/paraganglioma (Phaeo-Pgl) in SDHD than SDHB carriers: an Australian cohort study. 2019 , 49, 529-532	0
83	Rescue of TCA Cycle Dysfunction for Cancer Therapy. 2019 , 8,	15
82	Clinical utility of chromogranin A for the surveillance of succinate dehydrogenase B- and succinate dehydrogenase D-related paraganglioma. 2019 , 56, 163-169	4
81	Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers?. 2019 , 90, 31-46	16
80	Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management. 2020 , 35, 581-594	40
79	Clinical implications of the oncometabolite succinate in SDHx-mutation carriers. 2020 , 97, 39-53	21

78	Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked pheochromocytoma-paranglioma. 2020 , 57, 96-103	8
77	Practical Molecular Testing in a Clinical Genitourinary Service. 2020 , 144, 277-289	3
76	Oncometabolites in renal cancer. 2020 , 16, 156-172	49
75	Risk of metastatic pheochromocytoma and paraganglioma in mutation carriers: a systematic review and updated meta-analysis. 2020 , 57, 217-225	11
74	A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond pheochromocytoma and paraganglioma. 2020 , 93, 528-538	13
73	Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome. 2020 , 22, 2101-2107	9
72	and Non-Chromaffin Tumors: A Mediastinal Germ Cell Tumor Occurring in a Young Man with Germline Mutation. 2020 , 56,	1
71	Whole-Body MRI Surveillance of Cancer Predisposition Syndromes: Current Best Practice Guidelines for Use, Performance, and Interpretation. 2020 , 215, 1002-1011	9
70	Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study. 2020 , 11, 574662	5
69	Carney-Stratakis syndrome: A dyad of familial paraganglioma and gastrointestinal stromal tumor. 2020 , 15, 2071-2075	1
68	Succinate Dehydrogenase and Ribonucleic Acid Networks in Cancer and Other Diseases. 2020 , 12,	6
67	The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know. 2020 , 129, 1135-1143	3
66	Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas. 2020 , 12,	10
65	Current Approach of Functioning Head and Neck Paragangliomas: Case Report of a Young Patient with Multiple Asynchronous Tumors. 2020 , 2020, 6827109	
64	Tumor-specific prognosis of mutation-positive patients with head and neck paragangliomas. 2020 , 71, 1602-1612.e2	10
63	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. 2021 , 106, e1301-e1315	1
62	Pheochromocytoma/Paraganglioma, Medullary Thyroid Carcinoma, and Hereditary Endocrine Neoplasia Syndromes. 2021 , 491-527	1
61	Large Retroperitoneal Paraganglioma Associated with Germline Mutation of the Succinate Dehydrogenase Gene. 2021 , 8, 12-18	0

60	Pheochromocytoma and Paraganglioma. 2021 , 101-137	
59	From Diagnosis to Therapy-PET Imaging for Pheochromocytomas and Paragangliomas. 2021 , 22, 2	2
58	Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum. 2021 , 28, 6590-6600	3
57	Imaging evaluation of hereditary renal tumors: a pictorial review. 2021 , 39, 619-632	
56	Succinate dehydrogenase-deficient renal cell carcinoma: A case report and review of the literature. 2021 , 44, 692-693	
55	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. 2021 , 17, 435-444	12
54	Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency. 2021 , 12, 680609	1
53	Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?. 2021 , 22, 1721-1729	0
52	Long-Term Surgical Outcomes of Carotid Body Tumors With Pathological Fibrosis: A Cohort Study. 2021 , 11, 684600	1
51	Para-Gangliomas. 2021 , 189-208	
50	Hereditary Diseases Predisposing to Pheochromocytoma (VHL, NF-1, Paraganglioma Syndromes, and Novel Genes). 2019 , 111, 129-147	4
49	Genetics of Pheochromocytoma and Paraganglioma. 2017 , 85-103	0
48	Hereditary Renal Cell Carcinoma. 2017 , 19-82	1
47	[Hereditary kidney cancers: The pathologist's view in 2020]. 2020 , 40, 148-167	1
46	Birt-Hogg-Dubé syndrome-associated renal cell carcinoma: Histopathological features and diagnostic conundrum. 2020 , 111, 15-22	10
45	Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma. 2020 ,	3
44	An analysis of surveillance screening for SDHB-related disease in childhood and adolescence. 2019 , 8, 162-172	5
43	Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma. 2018 , 5, 14-22	14

42	Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality. 2018 , 9, 31664-31681	5
41	LASS5 Interacts with SDHB and Synergistically Represses p53 and p21 Activity. 2016 , 16, 582-90	3
40	Mutational Testing in Gastrointestinal Stromal Tumor. 2019 , 19, 688-697	4
39	Parangliomas and paraganglioma syndromes. 2011 , 10, Doc03	24
38	Pheochromocytoma and paraganglioma syndromes: genetics and management update. 2014 , 21, e8-e17	85
37	Epidemiology of Renal Cell Carcinoma. 2012 , 3-15	
36	Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma. 2012 , 289-324	
35	The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies. 2012 , 3-25	1
34	Familial and Hereditary Syndromes. 2013 , 39-50	
33	Cancer of the Kidney and Urogenital Tract. 2014 ,	
32	Inherited Renal Tumour Syndromes. 2014 , 469-479	
31	Genetics and Genito-Urinary Cancer. 2015 , 51-69	
30	Epidemiology of Renal Cell Carcinoma. 2015 , 3-16	
29	Adrenal Neuroendocrine Tumors: Pheochromocytoma and Neuroblastic Tumors. 2016 , 323-357	
28	Succinate Dehydrogenase Complex Deficiency Syndrome. 2016 , 28-31	
27	Paranglioma. 2018 , 401-411	
26	Intermittent Episodes of Sweating, Palpitations, and Hypertension. 2020 , 139-147	
25	Concurrent Birt-Hogg-Dub \ddot{u} Syndrom and Hereditary Paranglioma-Pheochromocytoma Syndrome Presenting as Metastatic Renal Cell Carcinoma in a 25-Year-Old Man: A Case Report. 2020 , 24, 1-6	0

24	Whole-Body MR Imaging. 2020 , 453-481		0
23	Metabologenomics of Pheochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. 2017 , 38, 69-100		38
22	A novel bi-allelic variant in the SDHB gene causes a severe mitochondrial complex II deficiency: a case report. 2021 , 212, 107039		
21	Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD.. 2021 ,		0
20	Paraganglioma of the cauda equina: A clinicopathologic study of 12 cases with demonstration of cytokeratin positivity.. 2022 , 57, 151887		
19	Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multi-center study.. 2022 ,		0
18	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases.. 2022 ,		0
17	Image_1.pdf. 2020 ,		
16	Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.. 2022 , 187, 85-90		
15	Metastatic pheochromocytomas and paragangliomas: where are we?. 2022 , 3008916221078621		1
14	Inherited Renal Tumour Syndromes. 2022 , 1039-1053		
13	Renal Tumors of Adults. 2021 , 91-344		
12	Hypothesis: Why Different Types of SDH Gene Variants Cause Divergent Tumor Phenotypes. <i>Genes</i> , 2022 , 13, 1025	4.2	0
11	Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes. 2022 ,		
10	Major heritable renal cell carcinoma syndromes: novel treatment options and future perspectives. <i>Current Opinion in Urology</i> , Publish Ahead of Print,	2.8	
9	Multifocal Paraganglioma in Teenager Presenting with Hypertension. 2022 ,		0
8	A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant.		0
7	SINGLE CENTRE EXPERIENCE WITH CAROTID BODY TUMOUR. 2022 , 49-51		0

- 6 SDHB exon 1 deletion: A recurrent germline mutation in Colombian patients with pheochromocytomas and paragangliomas. 13,
- 5 Hereditary head and neck paraganglioma: from basics to practical consequences. **2023**, 31, 111-117
- 4 Back to Biochemistry. **2023**, 16, 119-129
- 3 Reduced Risk of Corporal Tumors in Patients With Head and Neck Paragangliomas With p.Pro81Leu Mutations.
- 2 Succinate Dehydrogenase Mutations as Familial Pheochromocytoma Syndromes. **2023**, 32, 289-301
- 1 Influence of duration of preoperative treatment with phenoxybenzamine and secretory phenotypes on perioperative hemodynamics and postoperative outcomes in pheochromocytoma and paraganglioma. 14,